ADAM17 and diabetes mellitus: Mice heterozygous for Tace are protected from diet-induced insulin resistance and diabetes [34], whereas pharmacologic TACE-inhibition reduced hyperglycemia and vascular inflammation in diabetic mice heterozygous for the insulin receptor [33], as well as in fructose-fed rats [23].